IQVIA Plummets 9% Amid Investor Sentiment Decline... 3 Trillion Won Vanishes in a Day

IQVIA Holdings Inc. (NYSE: IQV), a U.S. healthcare data and clinical trial outsourcing company, saw its stock plunge 8.68% to close at $160 on the New York Stock Exchange. Trading volume topped one million shares, and its market capitalization fell to approximately $27.1 billion (about KRW 38 trillion), erasing roughly $2.2 billion (around KRW 3 trillion) in value in a single day. While volatility has been elevated since the start of the year, this decline is particularly pronounced even by recent standards.

In early February, the company reported fourth-quarter 2025 results and issued full-year 2026 revenue and earnings guidance; its adjusted earnings outlook missed Wall Street expectations, triggering an immediate post-announcement share drop of over 8%. In March and April, some analysts modestly trimmed price targets but maintained buy ratings—acknowledging IQVIA’s growth potential while remaining cautious about near-term performance headwinds.

Headquartered in Durham, North Carolina, IQVIA is a global healthcare IT and contract research organization formed in 2016 through the merger of Quintiles (a contract research organization) and IMS Health (a healthcare data analytics firm). The company provides services ranging from clinical trial design and management to real-world data analysis and physician prescribing data, serving as a core infrastructure partner in global biotech and pharmaceutical R&D and commercialization.